ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

RBCL RBC Life Sciences Inc (CE)

0.000067
0.00 (0.00%)
17 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
RBC Life Sciences Inc (CE) USOTC:RBCL OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.000067 0.00 01:00:00

Current Report Filing (8-k)

30/06/2015 6:27pm

Edgar (US Regulatory)




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24, 2015
______________________RBC Life Sciences, Inc.______________________
(Exact name of registrant as specified in its charter)
_______NEVADA_______
(State or other jurisdiction
of incorporation)
_______000-50417_________
(Commission
File Number)
_______91-2015186________
(IRS Employer
Identification No.)
2301 CROWN COURT, IRVING, TEXAS
(Address of principal executive offices)
____________75038_____________
(Zip Code)
Registrant's telephone number, including area code __________972-893-4000______________
__________________________N/A____________________________
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 24, 2015, immediately prior to the 2015 Annual Meeting of Shareholders (the “Annual Meeting”) of RBC Life Sciences, Inc. (the "Company"), Robert A. Kaiser resigned as a director of the Company. Mr. Kaiser, who served as Chair of the Audit Committee and as member of the Compensation Committee, was included in the Company’s proxy as a nominee for reelection to the Board of Directors at the Annual Meeting.
Mr. Kaiser chose to resign after he received a communication from Clinton H. Howard, the Company’s Chairman of the Board and beneficial owner of approximately 45% of the Company’s outstanding common stock, indicating that Mr. Howard intended to nominate and vote his shares at the Annual Meeting for the election of a candidate other than Mr. Kaiser. Mr. Kaiser’s letter of resignation is attached hereto as Exhibit 99.1.
Prior to the Annual Meeting, the Board of Directors consulted legal counsel, which advised that Mr. Howard’s contemplated actions to nominate another director candidate and cast his vote for that nominee at the Annual Meeting were in accordance with the Company’s bylaws, the laws of the State of Nevada (the State in which the Company is domiciled), and regulations promulgated by the Securities and Exchange Commission (the "SEC"). Mr. Howard denies that any of his actions with respect to this matter were in retaliation for any actions taken by Mr. Kaiser, and Mr. Howard and the Company have each self-reported to the SEC the transactions in Company securities described in Mr. Kaiser’s letter.

In relation to the statements in Mr. Kaiser’s letter regarding an additional investor relations program, the Company’s management decided against conducting this program because management does not believe that the potential benefits of the program justify the related cost. Further, management believes that the Company's current investor communications and SEC filings fully satisfy all public disclosure obligations in accordance with SEC regulations.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 24, 2015, the Company held the Annual Meeting for the following purposes:

1.
To elect two (2) persons to serve as Class II directors of the Company until the earlier of the 2018 Annual Meeting of Shareholders, their successors are duly elected and qualified, or their resignation or removal from office; and
2.
To ratify the appointment of Lane Gorman Trubitt, PLLC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2015.
At the close of business on April 28, 2015, the record date of the Annual Meeting, the Company had 2,212,350 shares of common stock issued and outstanding. The holders of a total of 1,920,719 shares of common stock were present at the Annual Meeting, either in person or by proxy, which total constituted a majority of the issued and outstanding shares on the record date for the Annual Meeting.
First Proposal:
The two persons named in the Company's proxy as nominees for the Board seats up for election were the incumbents, Steven E. Brown and Robert A. Kaiser. At the Annual Meeting, Charles A. Boyce, whose background information is provided below, was duly nominated from the floor as an additional candidate for director.
Pursuant to the vote conducted at the Annual Meeting, Mr. Brown and Mr. Boyce were duly elected as directors having received a plurality of the votes cast by shareholders present or represented by proxy. The votes cast at the Annual Meeting are set forth in the table below:
Nominee
 
For
 
Withheld
 
Broker Non-Votes
Steven E. Brown
 
1,472,950

 
1,750

 
446,019

Charles A. Boyce
 
972,900

 

 
446,019

Robert A. Kaiser
 
96,750

 
405,050

 
446,019










Charles A Boyce-
Mr. Boyce, age 85, has served since 2014 on the Board of Directors of the Las Colinas Association which serves as the permanent property owners association for all deed-restricted residential and commercial properties in the Las Colinas area of Dallas County.  Mr. Boyce has also been active in other charitable, professional, and civic organizations such as the Irving Symphony Association, Irving Arts Association, Irving Healthcare Foundation, and multiple Homeowner Associations since his retirement from Caltex Petroleum Corporation in 1994. Mr. Boyce started as General Tax Counsel, and was later Vice President - Finance, Director, Vice Chairman and Chief Financial Officer during his tenure at Caltex Petroleum Corporation from 1985 to1994. From 1969 to 1985, Mr. Boyce was Corporate Secretary, Associate General Counsel, and General Tax Counsel for Gulf Oil Corporation. Prior to joining Gulf Oil Corporation, Mr. Boyce served the Marathon Oil Company as Tax Counsel from 1964 to 1969. Mr. Boyce was also employed by Internal Revenue Service as a trial attorney from 1957 to 1964. Prior to joining the Internal Revenue Service, Mr. Boyce served in the US Air Force as a First Lieutenant from 1951 to 1953, and as a Major in the US Air Force Reserve from 1953 to 1967. Mr. Boyce obtained his Bachelor of Science degree from West Virginia University in 1951 and his Juris Doctor degree from Ohio State University in 1954.

The Board has determined that Mr. Boyce is an "independent director" as defined in the listing standards of NASDAQ and that he meets the definition of a "financial expert" as defined in Item 407(d) of Regulation S-K under the Exchange Act.
There are no arrangements or understandings between Mr. Boyce and any other person pursuant to which Mr. Boyce was nominated to be a Director.
Since the beginning of the Company’s last year, there have not been any transactions, or any currently proposed transactions, or series of similar transactions, in which the Company’s and its subsidiaries were a party and in which Mr. Boyce had a direct or indirect material interest.
Second Proposal:
The appointment of Lane Gorman Trubitt, PLLC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2015 was ratified by the holders of a majority of the shares of Common Stock present at the Annual Meeting as set forth below:
For
 
Against
 
Abstain
1,911,819

 

 
8,900


Item 9.01 Financial Statements and Exhibits.
(d)    Exhibits
Exhibit No.    Description
99.1
Letter of resignation from the Board of Directors effective June 24, 2015 from Robert A. Kaiser.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 30, 2015
                            
RBC Life Sciences, Inc.
 
By: /s/ Daley L. Seeker
Name: Daley L. Seeker
Title: Chief Financial Officer and Vice President-Finance







Exhibit 99.1


Mr. Steve Brown                via email and US Mail
Chief Executive officer
RBC Life Sciences
2301 Crown Plaza
Irving Texas 75038


Dear Steve

I am in receipt of the current correspondence from Mr. Howard to the Board of Directors concerning his nomination of Mr. Chuck Boyce to the board and his intent to vote his family’s shares for Mr. Boyce. I find this news disturbing since it is in direct conflict with a resolution passed in a recent Board meeting by the full Board including Mr. Howard and the Company’s proxy recommending my re-election. At this time, I have significant differences with the Company, particularly Mr. Howard. It is my belief this action is in retaliation to my efforts as special committee Chairman appointed by the board with the responsibility to investigate Mr. Howard for purchasing RBC stock while possibly in possession of material non-public information. The investigation resulted in a letter to the SEC requesting they take no action against the company, just this past week.

I strongly disagree with the Chairman of the Board using a loophole to bypass the nominating committee made up of independent directors and add a friend to the board. I further disagree with the use of the company’s attorneys to assist Mr. Howard in identifying the loophole at shareholder expense. The nominating committee is responsible for recommending nominees to Board members then the Board decides to nominate the candidate. In this instance he is bypassing the committee and the board. As the company’s largest shareholder Mr. Howard, alone, is using the loophole for his personal agenda, and not necessarily for the interests of the shares not owned by the Howard family.


Steve, it is my fundamental belief that any board of directors has a duty to all shareholders, not just the largest shareholder. As you are well aware, I have always wanted more disclosure to our shareholders, including my unsuccessful attempts to have management schedule a quarterly conference call to investors, like most public companies. Because of the above differences, I can no longer serve or try to protect the non-Howard public shareholders. For the above reasons, I will resign from the RBC board of directors effective 9am June 24, 2015.

_______________________________
Robert Kaiser Audit committee chairman

cc. David Ovesen
Lane Gorman Trubitt
2626 Howell suite 700
Dallas, TX 75204



1 Year RBC Life Sciences (CE) Chart

1 Year RBC Life Sciences (CE) Chart

1 Month RBC Life Sciences (CE) Chart

1 Month RBC Life Sciences (CE) Chart

Your Recent History

Delayed Upgrade Clock